Skip to content

Study · Non-randomized trial · 2000

1 result

[The experience with endolumbar application of cerebrolysin in hemispheric ischemic stroke].

Vilenskiĭ BS, Odinak MM, Shirokov EA, Vozniuk IA, Semenova GM, Grinevich TV

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2000Cited by 1 (Europe PMC)

PMID11247183 (opens in a new tab)PepBankPUB-11247183

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with hemispheric ischemic stroke, endolumbar then dropwise cerebrolysin significantly improved functional recovery versus placebo.

    In plain wordsIn patients with ischemic stroke, cerebrolysin injections improved functional recovery compared with placebo.

    Outcome
    IncreaseFunctional recovery
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    5 ml endolumbar injection followed by 10 ml dropwise injections · Endolumbar followed by dropwise injectionsAs given in this study (human).

    Source sentences

    Summary
    One endolumbar C injection (5 ml) made in the first 12 hours of stroke and after the subsequent therapy with dropwise C injections (10 ml) significantly enhanced the efficiency of therapy and improved the functional recovery of patients was observed 12 hours following.
    1 context sentence
    Summary · context
    The purpose of the investigation was to evaluate the efficiency of therapy of patients with hemispheric ischemic stroke with cerebrolysin (C) (using two different regimens of its injections) versus placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.